Today: 9 June 2026
Accenture stock price jumps nearly 8% late Thursday on Mistral AI partnership

Accenture stock price jumps nearly 8% late Thursday on Mistral AI partnership

New York, February 26, 2026, 15:55 EST — Regular session

  • Accenture shares climbed roughly 8% late in the session, reacting to news of a fresh AI partnership.
  • The consultancy keeps piling up AI deals, while investors argue over whether the technology will drive more demand or just chip away at billable hours.

Accenture plc shot up 7.9% to $206.70 late Thursday, snapping back from a $191.50 finish the day before. The consulting heavyweight inked a deal with French AI outfit Mistral AI.

Big tech stumbled as Nvidia’s numbers couldn’t reignite the AI rally, dragging the Nasdaq down. Yet, software names popped. “We’re seeing money now rotate back to the victims … the software companies,” said Joseph Sroka, chief investment officer at NovaPoint. Reuters

This rotation carries weight for Accenture. Investors have used the stock as a stand-in for the broader uncertainty around corporate tech budgets: is AI set to spark a fresh surge of projects, or will it end up reducing the work clients outsource to humans?

Accenture pitched Thursday’s agreement as a direct response to clients demanding more autonomy over their AI infrastructure—what the industry calls “sovereign” models, or in other words, systems that businesses can operate and govern themselves, in line with local requirements. “Our clients are looking for AI solutions that combine world class performance with the complete ownership that Mistral AI’s technology offers enterprises,” said Mauro Macchi, Accenture’s CEO for Europe, Middle East and Africa. On the other side, Mistral AI’s CEO Arthur Mensch said the partnership aims to equip customers with AI they can adapt for “performance, control, and customization.” Accenture Newsroom

Financial terms weren’t made public. The deal gives Accenture staff access to Mistral AI products, including Mistral AI Studio, according to Dow Jones Newswires. Mistral’s website lists IBM, Cisco, and SAP as users of its models.

Hot on the heels of the Mistral deal, Accenture has unveiled plans to acquire Verum Partners, a Brazilian infrastructure and capital projects management company with a staff of over 180. “Brazil’s investment cycle is accelerating,” said Rodolfo Eschenbach, who leads Accenture’s Latin America market unit, referencing activity in mining, grid modernization, and energy transition. The companies kept transaction terms under wraps. The deal still needs regulatory sign-off and other standard closing conditions. Accenture Newsroom

But it takes a while for partnerships and bolt-on deals to show up in the top line. Should clients keep cutting back on discretionary IT spending, or if AI tools start edging out external consultants in certain segments, the stock’s rebound might not last long.

Coming up on March 19, Accenture will break down its fiscal Q2 numbers. Investors will zero in on bookings and fresh signs of demand, hoping for a sharper read on how AI is changing the mix—what’s new, what’s shifting.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Intel stock slides as chip rally cools — what’s driving INTC today
Previous Story

Intel stock slides as chip rally cools — what’s driving INTC today

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal
Next Story

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

Go toTop